[go: up one dir, main page]

AU2001241541A1 - Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer - Google Patents

Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer

Info

Publication number
AU2001241541A1
AU2001241541A1 AU2001241541A AU4154101A AU2001241541A1 AU 2001241541 A1 AU2001241541 A1 AU 2001241541A1 AU 2001241541 A AU2001241541 A AU 2001241541A AU 4154101 A AU4154101 A AU 4154101A AU 2001241541 A1 AU2001241541 A1 AU 2001241541A1
Authority
AU
Australia
Prior art keywords
kits
assessment
therapy
prevention
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001241541A
Inventor
Wilson O. Endege
John E. Monahan
Robert Schlegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MILLENNIUM PREDICTIVE MEDICINE Inc
Original Assignee
MILLENNIUM PREDICTIVE MEDICINE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MILLENNIUM PREDICTIVE MEDICINE filed Critical MILLENNIUM PREDICTIVE MEDICINE
Publication of AU2001241541A1 publication Critical patent/AU2001241541A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2001241541A 2000-02-17 2001-02-20 Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer Abandoned AU2001241541A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US18331900P 2000-02-17 2000-02-17
US60183319 2000-02-17
US18986200P 2000-03-16 2000-03-16
US60189862 2000-03-16
US20745400P 2000-05-25 2000-05-25
US60207454 2000-05-25
US21131400P 2000-06-09 2000-06-09
US60211314 2000-06-09
US21900700P 2000-07-18 2000-07-18
US60219007 2000-07-18
US25528100P 2000-12-13 2000-12-13
US60255281 2000-12-13
PCT/US2001/005171 WO2001060860A2 (en) 2000-02-17 2001-02-20 Genes differentially expressed in human prostate cancer and their use

Publications (1)

Publication Number Publication Date
AU2001241541A1 true AU2001241541A1 (en) 2001-08-27

Family

ID=27558741

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001241541A Abandoned AU2001241541A1 (en) 2000-02-17 2001-02-20 Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer

Country Status (3)

Country Link
US (1) US20040259086A1 (en)
AU (1) AU2001241541A1 (en)
WO (1) WO2001060860A2 (en)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008765B1 (en) 1997-04-10 2006-03-07 The Johns Hopkins University PCA3, PCA3 genes, and methods of use
US20030166110A1 (en) * 1997-09-18 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20080050836A1 (en) * 1998-05-01 2008-02-28 Isabelle Guyon Biomarkers for screening, predicting, and monitoring benign prostate hyperplasia
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
DK1086223T3 (en) 1998-06-01 2009-11-30 Agensys Inc Novel serpentine transmembrane antigens expressed in human cancers and their applications
US20030166132A1 (en) * 1998-08-26 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030187196A1 (en) 1998-12-30 2003-10-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6551778B1 (en) * 1999-01-28 2003-04-22 Gen-Probe Incorporated Nucleic acid sequences for detecting genetic markers for cancer in a biological sample
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
EP1892249A1 (en) * 1999-09-01 2008-02-27 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2385477C (en) 1999-09-29 2009-11-03 Diagnocure Inc. Pca3 messenger rna species in benign and malignant prostate tissues
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
JP3964678B2 (en) 1999-10-28 2007-08-22 アジェンシス，インコーポレイテッド 36P6D5: Secretory tumor antigen
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
US7534417B2 (en) 2000-02-24 2009-05-19 Agensys, Inc. 103P2D6: tissue specific protein highly expressed in various cancers
US7070947B2 (en) 2000-02-29 2006-07-04 Millennium Pharmaceuticals, Inc. Human protein kinase, phosphatase, and protease family members and uses thereof
CA2404555A1 (en) * 2000-03-31 2001-10-11 Hyseq, Inc. Novel nucleic acids and polypeptides
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
JP2004501642A (en) 2000-06-28 2004-01-22 グライコフィ，　インコーポレイテッド Methods for producing modified glycoproteins
AU2001273452A1 (en) * 2000-07-13 2002-01-30 Millennium Pharmaceuticals, Inc. 47885, a novel human ubiquitin-activating enzyme and uses therefor
DE60136832D1 (en) * 2000-08-21 2009-01-15 Millenium Pharmaceuticals Inc ATCR-1, A HUMAN ACYLTRANSFERASE AND USES THEREOF
AU2002213084A1 (en) * 2000-10-11 2002-04-22 Avalon Pharmaceuticals Cancer-linked genes as targets for chemotherapy
AU2002215345A1 (en) * 2000-10-13 2002-04-22 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
US7037678B2 (en) * 2000-10-17 2006-05-02 California Institute Of Technology Claspin proteins and methods of use thereof
EP1349934A2 (en) 2000-11-20 2003-10-08 Diadexus, Inc. Compositions and methods relating to breast specific genes and proteins
US20020155463A1 (en) * 2000-12-01 2002-10-24 Zairen Sun Prostate polynucleotides and uses
WO2002046477A2 (en) 2000-12-07 2002-06-13 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
EP1356049A2 (en) * 2000-12-15 2003-10-29 Millennium Pharmaceuticals, Inc. Human sugar transporter proteins, potassium channel proteins, phospholipid transporter proteins and methods of use thereof
AU2002246708A1 (en) 2000-12-15 2002-08-12 Agensys, Inc. Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
US20090226915A1 (en) 2001-01-24 2009-09-10 Health Discovery Corporation Methods for Screening, Predicting and Monitoring Prostate Cancer
US6989441B2 (en) * 2001-02-15 2006-01-24 Millennium Pharmaceuticals, Inc. 25466, a human transporter family member and uses therefor
AU2002308285A1 (en) * 2001-02-21 2002-09-04 Bayer Aktiengesellschaft Regulation of human phosphatidic acid-preferring phospholipase a1
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
GB0106782D0 (en) * 2001-03-19 2001-05-09 Univ The Glasgow Polypeptides, methods and means
US20040006205A1 (en) * 2001-04-03 2004-01-08 Li Li Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
WO2002083921A2 (en) * 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
WO2002083068A2 (en) * 2001-04-10 2002-10-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 121p2a3 useful in treatment and detection of cancer
US7309760B2 (en) * 2001-04-17 2007-12-18 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
US7195868B2 (en) * 2001-04-18 2007-03-27 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention, and therapy of human cancers
GB0112453D0 (en) * 2001-05-22 2001-07-11 Pharma Pacific Pty Ltd Interferon-alpha induced gene
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7705120B2 (en) 2001-06-21 2010-04-27 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20050085627A1 (en) 2001-06-21 2005-04-21 Youming Zhang Atopy
JP4098236B2 (en) * 2001-08-24 2008-06-11 久光製薬株式会社 Nucleic acids with differential expression between hepatoblastoma and normal liver
EP1429793B1 (en) 2001-09-06 2015-02-25 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP2143438B1 (en) 2001-09-18 2011-07-13 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumors
US20040038877A1 (en) * 2001-10-02 2004-02-26 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040166490A1 (en) * 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20030219768A1 (en) * 2001-11-02 2003-11-27 Beebe Jean S. Lung cancer therapeutics and diagnostics
JP4200100B2 (en) 2001-11-07 2008-12-24 アジェンシス，インコーポレイテッド Nucleic acids and corresponding proteins referred to as 161P2F10B useful in cancer treatment and detection
EP1310552B1 (en) 2001-11-09 2007-06-13 Proteologics, Inc. Posh nucleic acids, polypeptides and related methods
AU2002351332A1 (en) * 2001-12-07 2003-06-23 Chiron Corporation Endogenous retrovirus polypeptides linked to oncogenic transformation
JP4646315B2 (en) 2001-12-07 2011-03-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Endogenous retroviruses up-regulated in prostate cancer
US20060275747A1 (en) * 2001-12-07 2006-12-07 Hardy Stephen F Endogenous retrovirus up-regulated in prostate cancer
US7449548B2 (en) 2001-12-07 2008-11-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer
US20030144188A1 (en) * 2002-01-15 2003-07-31 Biaoyang Lin Androgen regulated nucleic acid molecules and encoded proteins
US8008012B2 (en) 2002-01-24 2011-08-30 Health Discovery Corporation Biomarkers downregulated in prostate cancer
JPWO2003068973A1 (en) * 2002-02-13 2005-06-02 暉勝 有馬 DNA sequences and encoded polypeptides useful for the diagnosis of hepatitis
DE10211088A1 (en) * 2002-03-13 2003-09-25 Ugur Sahin Gene products differentially expressed in tumors and their use
FR2837391B1 (en) 2002-03-22 2007-04-20 Gene Signal REGULATORY GENES OF ANGIOGENESIS, PHARMACEUTICAL PREPARATIONS CONTAINING SAME AND APPLICATIONS THEREOF
US7803906B2 (en) 2002-03-22 2010-09-28 Gene Signal International Sa Composition comprising an angiogenesis related protein
EP1565488A4 (en) * 2002-05-15 2007-10-03 Avalon Pharmaceuticals CANCER-RELATED GENE AS A TARGET FOR CHEMOTHERAPY
AU2003241456A1 (en) * 2002-05-16 2003-12-02 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
AU2003241179C1 (en) * 2002-06-06 2010-11-25 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
ATE545651T1 (en) * 2002-06-13 2012-03-15 Novartis Vaccines & Diagnostic VECTORS FOR EXPRESSING HML-2 POLYPEPTIDES
US20060189518A1 (en) * 2002-06-26 2006-08-24 Takeda Pharmaceutical Company Limited Preventing/remedies for cancer
DE10230692A1 (en) * 2002-07-08 2004-02-12 Epigenomics Ag Methods and nucleic acids for the analysis of methylation patterns within the DD3 gene
US20040081653A1 (en) * 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
AU2002951346A0 (en) * 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
DK2891666T3 (en) 2002-10-16 2017-10-02 Purdue Pharma Lp Antibodies that bind cell-associated CA 125 / O722P and methods for its use
KR20050056250A (en) * 2002-10-18 2005-06-14 주식회사 엘지생명과학 Gene families associated with cancers
JP2006517785A (en) * 2002-10-29 2006-08-03 ジェネンテック・インコーポレーテッド Novel compositions and methods for the treatment of immune related diseases
AU2003300815A1 (en) * 2002-12-05 2004-06-30 Incyte Corporation Protein modification and maintenance molecules
US20050282170A1 (en) 2003-02-07 2005-12-22 Diagnocure Inc. Method to detect prostate cancer in a sample
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
WO2005017104A2 (en) * 2003-06-16 2005-02-24 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
WO2004113571A2 (en) * 2003-06-26 2004-12-29 Exonhit Therapeutics Sa Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
US20080153104A1 (en) 2003-08-08 2008-06-26 Hiroyuki Aburantai Gene Overexpressed in Cancer
DE10345011A1 (en) * 2003-09-22 2005-04-14 Staub, Eike Use of metarring-binding substances for the diagnosis and treatment of cancer
DE10344799A1 (en) * 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
AU2015201738B2 (en) * 2003-09-26 2016-10-13 Biontech Ag Identification of tumour-associated cell surface antigens for diagnosis and therapy
CN100484568C (en) * 2003-12-11 2009-05-06 中国人民解放军军事医学科学院放射与辐射医学研究所 Antibiosis usage of a family of protein
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2005080597A1 (en) * 2004-02-24 2005-09-01 Oncotherapy Science, Inc. Method for diagnosing colorectal cancers
WO2005085865A2 (en) * 2004-03-09 2005-09-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with thyroid hormone receptor beta (thrb)
EP1727831A1 (en) * 2004-03-23 2006-12-06 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
PT1742966E (en) 2004-04-22 2014-02-05 Agensys Inc Antibodies and molecules derived therefrom that bind to steap-1 proteins
WO2005111213A1 (en) * 2004-05-18 2005-11-24 Kurume University Target gene mimitin of myc
WO2006008005A2 (en) * 2004-07-23 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 2 (hzf2)
WO2006022689A1 (en) * 2004-08-06 2006-03-02 Applera Corporation Method and compositions for treating diseases targeting cd51
US8435507B2 (en) * 2004-08-19 2013-05-07 University Of Maryland Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
US11105808B2 (en) 2004-11-12 2021-08-31 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
AU2006205999B2 (en) * 2005-01-14 2011-09-22 University Of Guelph Nitrogen-regulated sugar sensing gene and protein and modulation thereof
US20070250956A1 (en) 2005-01-14 2007-10-25 University Of Guelph Nitrogen-Regulated Sugar Sensing Gene and Protein and Modulation Thereof
WO2006086345A2 (en) * 2005-02-07 2006-08-17 The Trustees Of Columbia University In The City Of New York Methods to treat or prevent hormone-resistant prostate cancer using sirna specific for protocadherin-pc, or other inhibitors of protocadherin-pc expression or activity
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
WO2006105488A2 (en) 2005-03-31 2006-10-05 Agensys, Inc. Antibodies and related molecules that bind to 161p2f10b proteins
US8350009B2 (en) 2005-03-31 2013-01-08 Agensys, Inc. Antibodies and related molecules that bind to 161P2F10B proteins
US20060263788A1 (en) * 2005-05-17 2006-11-23 Ken-Shwo Dai Human kinase interacting protein 2 (KIP2)-related gene variant (KIP2V1) associated with prostate cancer
EP1728799B1 (en) * 2005-06-02 2008-08-20 Bioptik Technology, Inc. Human kinase interacting protein 2 (KIP2)-related gene variant (KIP2V1) associated with prostate cancer
CA2622295C (en) 2005-09-12 2019-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20070071755A1 (en) * 2005-09-27 2007-03-29 David Balasundaram Novel nucleolar GTPases and method for controlling proliferation of cells
WO2007041359A2 (en) * 2005-09-29 2007-04-12 The Regents Of The University Of California Compositions and methods relating to cornelia de lange syndrome
US20090269744A1 (en) * 2005-10-28 2009-10-29 Exonhit Therapeutics Sa Cancer detection method
DE102005059242A1 (en) * 2005-12-12 2007-06-14 Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten Molecular markers for tumor diagnosis and therapy
EP1900824A1 (en) * 2006-09-14 2008-03-19 Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts Gene expression signature for the prognosis, diagnosis and therapy of prostate cancer and uses thereof
LT2845866T (en) 2006-10-27 2017-07-10 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
WO2008052238A1 (en) * 2006-11-01 2008-05-08 The University Of Sydney Treatment of urological cancer
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
CA2685551C (en) 2007-05-16 2016-11-29 Gene Signal International Sa Anti-tumor drug, medicament, composition, and use thereof
ATE533861T1 (en) 2007-07-06 2011-12-15 Univ Michigan MIPOL1-ETV1 GENE ARRANGEMENTS
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
WO2009140741A1 (en) * 2008-05-23 2009-11-26 The University Of Queensland Agents and methods for diagnosing the presence or risk of prostate cancer
US20110136683A1 (en) * 2008-05-28 2011-06-09 Genomedx Biosciences, Inc. Systems and Methods for Expression-Based Discrimination of Distinct Clinical Disease States in Prostate Cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
DE102008031699A1 (en) * 2008-07-04 2010-01-14 Protagen Ag Marker sequences for prostate inflammatory diseases, prostate cancer and their use
US8426133B2 (en) 2009-05-26 2013-04-23 Quest Diagnostics Investments Incorporated Methods for detecting gene dysregulation by intragenic differential expression
CN102712953A (en) 2009-09-17 2012-10-03 密歇根大学董事会 Recurrent gene fusions in prostate cancer
WO2011079191A1 (en) 2009-12-23 2011-06-30 Quest Diagnostics Investments Incorporated Tmprss2 for the diagnosis of prostate disease
TWI504410B (en) 2010-02-08 2015-10-21 Agensys Inc Antibody drug conjugates (adc) that bind to 161p2f10b proteins
EP3903812A1 (en) 2010-09-29 2021-11-03 Agensys, Inc. Antibody drug conjugates (adc) that bind to 191p4d12 proteins
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
EP2487251A1 (en) 2011-02-13 2012-08-15 Protagen AG Marker sequences for the diagnosis of prostate carcinoma and use of same
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
CA2881627C (en) 2012-08-16 2024-09-10 Mayo Foundation For Medical Education And Research Cancer diagnostics using biomarkers
DK2991656T3 (en) 2013-05-01 2020-03-23 Ionis Pharmaceuticals Inc COMPOSITIONS AND PROCEDURES FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
US10188712B2 (en) * 2013-07-30 2019-01-29 Biontech Ag Tumor antigens for determining cancer therapy
EP2878678A1 (en) 2013-12-02 2015-06-03 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. RNA-biomarkers for diagnosis of prostate cancer
FR3016638B1 (en) * 2014-01-23 2018-04-13 Centre National De La Recherche Scientifique - Cnrs - NEW METHOD OF DETECTING PROSTATE CANCER
WO2016087430A1 (en) * 2014-12-01 2016-06-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel RNA-biomarker signature for diagnosis of prostate cancer
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
WO2018067900A1 (en) 2016-10-06 2018-04-12 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds
AU2018210695B2 (en) 2017-01-20 2024-07-18 The University Of British Columbia Molecular subtyping, prognosis, and treatment of bladder cancer
CA3055925A1 (en) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018184966A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Antibodies binding to steap-1
CA3062716A1 (en) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
JP7514834B2 (en) 2018-12-03 2024-07-11 アジェンシス，インコーポレイテッド Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004149A2 (en) * 1998-07-14 2000-01-27 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer

Also Published As

Publication number Publication date
US20040259086A1 (en) 2004-12-23
WO2001060860A3 (en) 2002-06-13
WO2001060860A2 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
AU2001241541A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AU2002337657A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
AU2001229340A1 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2074201A (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
AU2002322280A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2001236519A1 (en) Identification, assessment, prevention, and therapy of prostate cancer
AU4592601A (en) Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU7994200A (en) Compositions and methods for therapy and diagnosis of prostate cancer
AU2002324451A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
HUP0203968A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2003302892A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2003293194A1 (en) Compositions and methods for treating prostate cancer
AU2003226676A1 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
AUPQ923100A0 (en) Treatment of prostate cancer
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001252945A1 (en) Compositions and methods for therapy and diagnosis of colon cancer
AU7701100A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU2001268467A1 (en) Identification of genes and compounds for treatment of cancer
AU2002246519A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer